bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
Company profile
Ticker
BHC
Exchange
Website
CEO
Thomas J. Appio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIOVAIL Corp, BIOVAIL CORP INTERNATIONAL, BIOVAIL CORPORATION INTERNATIONAL, Valeant Pharmaceuticals International, Inc.
SEC CIK
Corporate docs
Subsidiaries
Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • AcuFocus Australia • Bausch Health Australia Pty Limited • Bausch & Lomb (Australia) Pty Limited • Bausch & Lomb Australia Holdings Pty Limited • Solta Medical Australia Pty Limited • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. • PharmaSwiss BH Društvo za trgovinu na veliko d.o.o. ...
BHC stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Bausch Health Announces Fourth-quarter and Full-year 2023 Results
22 Feb 24
8-K
Bausch Health Announces Board Refreshment
1 Feb 24
8-K/A
Financial Statements and Exhibits
13 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Bausch Health Announces Third-quarter 2023 Results
2 Nov 23
8-K
Bausch Health’s Bausch + Lomb Announces About Bausch Health
29 Sep 23
Transcripts
BHC
Earnings call transcript
2023 Q3
2 Nov 23
BHC
Earnings call transcript
2023 Q2
3 Aug 23
BHC
Earnings call transcript
2023 Q2
3 Aug 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2023 Q1
4 May 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q4
23 Feb 23
BHC
Earnings call transcript
2022 Q3
3 Nov 22
BHC
Earnings call transcript
2022 Q2
9 Aug 22
BHC
Earnings call transcript
2022 Q2
9 Aug 22
Latest ownership filings
4
John Paulson
1 Apr 24
4
BRETT ICAHN
1 Apr 24
4
RUSSEL C ROBERTSON
1 Apr 24
4
AMY B WECHSLER
1 Apr 24
4
John S Barresi
4 Mar 24
4
THOMAS APPIO
4 Mar 24
4
Seana Carson
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
GOLDENTREE ASSET MANAGEMENT LP
13 Feb 24
SC 13D/A
ICAHN CARL C
7 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm | 780.00 mm |
Cash burn (monthly) | (no burn) | (no burn) | 108.67 mm | 8.00 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 722.90 mm | 53.22 mm | n/a | n/a |
Cash remaining | n/a | n/a | 57.10 mm | 726.78 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 0.5 | 90.8 | n/a | n/a |
Institutional ownership, Q3 2023
81.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 223 |
Opened positions | 35 |
Closed positions | 41 |
Increased positions | 44 |
Reduced positions | 66 |
13F shares | Current |
---|---|
Total value | 2.29 tn |
Total shares | 292.79 mm |
Total puts | 20.81 mm |
Total calls | 11.56 mm |
Total put/call ratio | 1.8 |
Largest owners | Shares | Value |
---|---|---|
Icahn Carl C Et Al | 34.72 mm | $285.42 bn |
Paulson & Co. | 26.44 mm | $217.33 bn |
Goldentree Asset Management | 23.99 mm | $197.18 bn |
NMR Nomura | 18.09 mm | $148.67 bn |
BEN Franklin Resources | 15.80 mm | $129.89 bn |
National Bank of Canada | 15.66 mm | $127.49 bn |
VA Partners I | 14.43 mm | $135.65 mm |
Hudson Bay Capital Management | 11.50 mm | $94.53 bn |
Vanguard | 11.49 mm | $94.43 bn |
BMO Bank of Montreal | 10.87 mm | $94.00 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Paulson John | Common Shares, No Par Value | Grant | Acquire A | No | No | 10.61 | 5,890 | 62.49 k | 208,309 |
29 Mar 24 | Brett Icahn | Common Shares, No Par Value | Grant | Acquire A | No | No | 10.61 | 3,122 | 33.12 k | 108,500 |
29 Mar 24 | Robertson Russel C | Common Shares, No Par Value | Grant | Acquire A | No | No | 10.61 | 2,945 | 31.25 k | 225,279 |
29 Mar 24 | Wechsler Amy B | Common Shares, No Par Value | Grant | Acquire A | No | No | 10.61 | 647 | 6.86 k | 169,906 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 133 | 1.30 k | 499,905 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 1,561 | 15.30 k | 500,038 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 199 | 1.95 k | 501,599 |
4 Mar 24 | Seana Carson | Common Shares, No Par Value | Sell | Dispose S | No | Yes | 9.8 | 4,420 | 43.32 k | 501,798 |
1 Mar 24 | Seana Carson | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 511 | 5.05 k | 506,218 |
1 Mar 24 | Seana Carson | Common Shares, No Par Value | Payment of exercise | Dispose F | No | No | 9.89 | 16,973 | 167.86 k | 506,729 |
News
RBC Capital Reiterates Sector Perform on Bausch Health Companies, Maintains $12 Price Target
12 Apr 24
Bausch Health Companies Appeals Court Ruling Out On Bausch Health/Salix Vs Norwich On Xifaxan
11 Apr 24
Acne Vulgaris Treatment PrARAZLO Now Available To Patients Through British Columbia PharmaCare Public Drug Plan
11 Apr 24
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
5 Apr 24
RBC Capital Maintains Sector Perform on Bausch Health Companies, Raises Price Target to $12
5 Apr 24
Press releases
Bausch Health to Announce First-Quarter 2024 Results on May 2
11 Apr 24
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029
11 Apr 24
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
11 Apr 24
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
5 Apr 24
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
3 Apr 24